Showing results (141-150 of 410) with videos related to
Sort By:
Pageof 41
Cancer Immunology Research|November 8, 2015
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor CellsKathleen M Mahoney, Heather Sun, Xiaoyun Liao, et al.Cancer Research|January 14, 2010
Modulation of T-cell activation by malignant melanoma initiating cellsTobias Schatton, Ute Schütte, Natasha Y Frank, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cellMarcus O Butler, Jeng-Shin Lee, Sascha Ansén, et al.Cancer Immunology Research|April 30, 2014
Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumabJianda Yuan, Jun Zhou, Zhiwan Dong, et al.Cancer Immunology Research|February 12, 2016
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung CancerMizuki Nishino, Emily S Chambers, Curtis R Chong, et al.European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.STAR Protocols|March 4, 2022
Mass cytometry staining for human bone marrow clinical samplesMargaret Hallisey, Jenna Dennis, Charlotte Abrecht, et al.Cancer|September 14, 2020
Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastasesJack M Qian, Allison M Martin, Kate Martin, et al.Journal for Immunotherapy of Cancer|August 16, 2017
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumabPhilip Friedlander, Karl Wassmann, Alan M Christenfeld, et al.The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.Pageof 41